Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs 10X Genomics Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while 10X Genomics Inc trades at $82.5 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 26.6× JPMorgan Diversified Return International Eqty ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and 10X Genomics Inc for 91 Days on average.
| JPIN | TXG | |
|---|---|---|
Market Cap | $378.77M | $10.07B |
Volume | 13,861 | 5,657,286 |
52-Week High | $77.80 | $97.74 |
52-Week Low | $64.96 | $11.48 |
Typical Hold Time | 120 Days | 91 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.01, up 0.1% on the day, but technical indicators signal a bearish trend with 21 sell signals versus 2 buy signals. The ETF exhibits oversold conditions with RSI readings below 25, while moving averages and ADX reinforce downward momentum. A dividend of $0.51 is scheduled for payment in September 2026, offering income potential amid weak price action.
The outlook remains cautious due to strong bearish technical pressure, though oversold RSI levels may attract contrarian buyers. Risks include persistent selling pressure and reliance on international equity markets. Investment appeal hinges on dividend yield and potential mean reversion if broader market sentiment improves.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
